IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting
Portfolio Pulse from
IMUNON presented positive data from its Phase 2 OVATION 2 clinical trial of IMNN-001 in advanced ovarian cancer at the SITC 39th Annual Meeting. The trial showed a 35% improvement in overall survival and a 25% improvement in progression-free survival when IMNN-001 was combined with standard-of-care chemotherapy, compared to standard-of-care alone.
November 07, 2024 | 3:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IMUNON's Phase 2 OVATION 2 trial of IMNN-001 in advanced ovarian cancer showed significant improvements in survival rates, which could positively impact the company's stock price.
The positive results from the Phase 2 trial of IMNN-001, showing significant improvements in survival rates, are likely to boost investor confidence and positively impact IMUNON's stock price. The data presented at a major conference further validates the potential of IMNN-001, making it a significant development for the company.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100